Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2021

01-12-2021 | Breast Cancer | Global Health Services Research

Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group

Authors: Candice A. M. Sauder, MD, Qian Li, MS, Richard J. Bold, MD, Kathryn J. Ruddy, MD, Theresa H. M. Keegan, PhD

Published in: Annals of Surgical Oncology | Issue 13/2021

Login to get access

Abstract

Background

Secondary cancers account for 16% of all new cancer diagnoses, with breast cancer (BC) the most common secondary cancer. We have shown that secondary BC has unique characteristics and decreased survival compared with primary BC in adolescent and young adults (AYA; 15–39 years old). However, older BC populations are less well studied.

Methods

Females (age ≥ 15 years) diagnosed with primary BC during 1991–2015 (n = 377,167) and enrolled in the California Cancer Registry were compared with those with secondary BC (n = 37,625) by age (15–39, 40–64, ≥ 65 years). We examined BC-specific survival (BCSS) accounting for other causes of death as a competing risk using multivariable Cox proportional hazards regression.

Results

Most secondary BC patients were of older age (15–39, n = 777; 40–64, n = 15,848; ≥ 65, n = 21,000). Compared with primary BC treatment, secondary BCs were more often treated with mastectomy and less often with chemotherapy and/or radiation. BCSS was shorter in secondary BC patients than primary BC patients, but the survival difference between secondary and primary BC diminished with age [15–39 hazard ratio (HR): 2.09, 95% confidence interval (CI) 1.83–2.39; 40–64 HR: 1.51; 95% CI 1.44–1.58; ≥ 65 HR: 1.14; 95% CI 1.10–1.19]. Survival differences were most pronounced in women with hormone receptor positive disease and Hispanic and Asian/Pacific Islanders 40–64 years of age.

Conclusions

When BC is diagnosed following a prior cancer of any organ site, BCSS is worse than when compared with patients for whom BC is the primary diagnosis, suggesting that we may need to tailor our treatments for women with secondary BC.
Literature
1.
go back to reference Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.CrossRef Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.CrossRef
2.
go back to reference Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomark Prev. 2006;15(11):2020–6.CrossRef Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomark Prev. 2006;15(11):2020–6.CrossRef
3.
go back to reference Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016;122(1):116–23.CrossRef Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016;122(1):116–23.CrossRef
4.
go back to reference Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. New Engl J Med. 2015;373(26):2499–511.CrossRef Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. New Engl J Med. 2015;373(26):2499–511.CrossRef
5.
go back to reference Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–7.CrossRef Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–7.CrossRef
6.
go back to reference Sadler C, Goldfarb M. Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer. 2015;121(8):1295–302.CrossRef Sadler C, Goldfarb M. Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer. 2015;121(8):1295–302.CrossRef
7.
go back to reference Sauder CAM, Li Q, Othieno A, et al. Characteristics and outcomes for secondary breast cancer in childhood, adolescent, and young adult cancer survivors treated with radiation. Cancer Epidemiol Biomark Prevent. 2020;29(9):1767–74.CrossRef Sauder CAM, Li Q, Othieno A, et al. Characteristics and outcomes for secondary breast cancer in childhood, adolescent, and young adult cancer survivors treated with radiation. Cancer Epidemiol Biomark Prevent. 2020;29(9):1767–74.CrossRef
8.
go back to reference Valdivieso M, Kujawa AM, Jones T, Baker LH. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci. 2012;9(2):163–73.CrossRef Valdivieso M, Kujawa AM, Jones T, Baker LH. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci. 2012;9(2):163–73.CrossRef
9.
go back to reference Hiatt RA, Tai CG, Blayney DW, et al. Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond. J. Natl. Cancer Inst. 2015;107(5). Hiatt RA, Tai CG, Blayney DW, et al. Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond. J. Natl. Cancer Inst. 2015;107(5).
10.
go back to reference Goldfarb M, Rosenberg AS, Li Q, Keegan THM. Impact of latency time on survival for adolescents and young adults with a second primary malignancy. Cancer. 2018;124(6):1260–8.CrossRef Goldfarb M, Rosenberg AS, Li Q, Keegan THM. Impact of latency time on survival for adolescents and young adults with a second primary malignancy. Cancer. 2018;124(6):1260–8.CrossRef
11.
go back to reference Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109(9):1721–8.CrossRef Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109(9):1721–8.CrossRef
12.
go back to reference Keegan THM, Press DJ, Tao L, et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res. 2013;15(5):R95.CrossRef Keegan THM, Press DJ, Tao L, et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res. 2013;15(5):R95.CrossRef
13.
go back to reference Keegan TH, DeRouen MC, Parsons HM, et al. Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult hodgkin lymphoma: a population-based study. Cancer Epidemiol Biomark Prev. 2016;25(2):264–73.CrossRef Keegan TH, DeRouen MC, Parsons HM, et al. Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult hodgkin lymphoma: a population-based study. Cancer Epidemiol Biomark Prev. 2016;25(2):264–73.CrossRef
14.
go back to reference Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12(8):703–11.CrossRef Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12(8):703–11.CrossRef
15.
go back to reference Brandt J, Garne JP, Tengrup I, Manjer J. Age at diagnosis in relation to survival following breast cancer: a cohort study. World J Surg Oncol. 2015;13(1):33.CrossRef Brandt J, Garne JP, Tengrup I, Manjer J. Age at diagnosis in relation to survival following breast cancer: a cohort study. World J Surg Oncol. 2015;13(1):33.CrossRef
16.
go back to reference El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006;6:194.CrossRef El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006;6:194.CrossRef
17.
go back to reference Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer. 1997;33(3):425–8.CrossRef Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer. 1997;33(3):425–8.CrossRef
18.
go back to reference Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.CrossRef Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.CrossRef
19.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.CrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.CrossRef
21.
go back to reference Boyer-Chammard A, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. Cancer Detect Prev. 1999;23(6):463–73.CrossRef Boyer-Chammard A, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. Cancer Detect Prev. 1999;23(6):463–73.CrossRef
22.
go back to reference Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008;112(1):171–80.CrossRef Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008;112(1):171–80.CrossRef
23.
go back to reference Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009;101(14):984–92.CrossRef Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009;101(14):984–92.CrossRef
24.
go back to reference Maskarinec G, Sen C, Koga K, Conroy SM. Ethnic differences in breast cancer survival: status and determinants. Womens Health (Lond). 2011;7(6):677–87.CrossRef Maskarinec G, Sen C, Koga K, Conroy SM. Ethnic differences in breast cancer survival: status and determinants. Womens Health (Lond). 2011;7(6):677–87.CrossRef
25.
go back to reference McCracken M, Olsen M, Chen MS Jr, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese Ethnicities. CA Cancer J Clin. 2007;57(4):190–205.CrossRef McCracken M, Olsen M, Chen MS Jr, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese Ethnicities. CA Cancer J Clin. 2007;57(4):190–205.CrossRef
26.
go back to reference Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73.CrossRef Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73.CrossRef
27.
go back to reference Miller KD, Goding Sauer A, Ortiz AP, et al. Cancer statistics for hispanics/latinos. CA Cancer J Clin. 2018;68(6):425–45.CrossRef Miller KD, Goding Sauer A, Ortiz AP, et al. Cancer statistics for hispanics/latinos. CA Cancer J Clin. 2018;68(6):425–45.CrossRef
28.
go back to reference Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7.CrossRef Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7.CrossRef
29.
go back to reference Brown M, Bauer K, Pare M. Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004. Breast Cancer Res Treat. 2010;120(1):217–27.CrossRef Brown M, Bauer K, Pare M. Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004. Breast Cancer Res Treat. 2010;120(1):217–27.CrossRef
Metadata
Title
Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group
Authors
Candice A. M. Sauder, MD
Qian Li, MS
Richard J. Bold, MD
Kathryn J. Ruddy, MD
Theresa H. M. Keegan, PhD
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-10340-3

Other articles of this Issue 13/2021

Annals of Surgical Oncology 13/2021 Go to the issue